By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company ...

Novavax, Inc. (Nasdaq: NVAX) has entered into a license agreement with Pfizer for use of Novavax's Matrix-M® adjuvant. Under ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Shares rose 6.6% Monday on new partnership strategy outlined at J.P. Morgan conference. Sanofi deal and cost cuts drive ...

The vaccines subsector received a big fillip from Covid, but its potential extends far beyond combating pandemics. Dr Mike ...

What Happened? Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 3% in the morning session after reports revealed that its JN.1 Covid-19 vaccine became available at some GP clinics ...

Long-term data suggest Moderna’s personalized melanoma shot provides “durable tumor control,” one analyst said. Elsewhere, ...

Novavax is eligible to receive tiered royalties in the high mid-single digit range on sales of any Pfizer products that use Matrix-M. Novavax, Inc. (NVAX) shares climbed 6% higher in pre-market ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Gaithersburg’s Novavax has struck a deal to give Pfizer the rights to its adjuvant technology — for a potential $530 million ...